Atlas Venture — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Comanche Biopharma is a biopharmaceutical company developing evidence-based therapies for preeclampsia and other life-threatening conditions of pregnancy, with a focus on maternal and neonatal health.
BiotechFemTechHealthtechConcord, US
Arthur Levin(Director)Brendan Bulik-Sullivan(Director)Muzammil Mansuri(Director)Paul Antinori(Executive Officer)Allison August(Executive Officer)Ann Taylor(Director)
Board seatDavid Grayzel· per SEC Form D
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Matthew Patterson(Director)Kevin Bitterman(Director)Jeff Goater(Director)
Board seatKevin Bitterman· per SEC Form D
BiotechCambridge, US
Daniel J Mandell(Executive Officer, Director)Tracey Lodie(Executive Officer)Christopher Gregg(Director)Geoffrey Smith(Director)
BoardMing Fang(Director)Bruce Beutel(Director)
Board seatKevin Bitterman· per SEC Form D · $60.4M raise · filed Jul 2024
BiotechBoston, US
Adam Friedman(Executive Officer, Director)Andrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)Gary Glick(Executive Officer, Director)
Board seatJean-François Formela· per SEC Form D
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.